Generative AI in pharmaceuticals: Use cases, operating model, governance, and future trends

Pharmaceuticals presents one of the strongest enterprise use cases for generative and agentic AI because its workflows sit at the intersection of regulated documents, structured data, scientific judgment, exception management, and controlled handoffs. A pharmaceutical organization does far more than discover and manufacture medicines. It validates assays, designs protocols, authors clinical study reports, classifies adverse events, investigates deviations, reconciles batch records, prepares submission dossiers, responds to health authority questions, and documents decisions across systems such as electronic lab notebooks, laboratory information management systems, clinical data platforms, regulatory information management systems, pharmacovigilance safety databases, quality management systems, and manufacturing execution systems.

These activities create an ideal environment for generative and agentic AI. Traditional analytics and machine learning already help pharma teams predict molecular properties, assess risk, detect anomalies, and classify records. Generative AI extends this capability by reading and extracting evidence from regulated documents, drafting scientific and compliance narratives, comparing records against standards, retrieving controlled guidance, and summarizing complex clinical, regulatory, quality, and operational contexts. Agentic AI goes further by coordinating multi-step workflows across approved systems while keeping human reviewers accountable at each control point.

The value opportunity is increasingly visible. Deloitte [1] estimates that AI could unlock $5 billion to $7 billion in value for life sciences companies, while McKinsey [2] places the generative AI opportunity in biopharmaceutical operations alone at $4 billion to $7 billion annually.

However, the value of generative AI in pharmaceuticals does not come from isolated pilots or generic chatbots. It comes from embedding AI into real, regulated workflows. A regulatory affairs manager preparing a health authority response needs AI that can connect agency questions to approved source evidence. A medical writer drafting a clinical study report needs AI that can work with protocols, statistical outputs, safety narratives, and approved study materials. A quality assurance reviewer assessing a deviation needs AI that can compare investigation details against SOPs, batch records, and prior related events. Similarly, a pharmacovigilance physician, CMC author, or medical information specialist needs AI that understands the workflow, the source systems, the regulatory context, and the output required for human review.

That is why generative AI use cases in pharmaceuticals should be mapped at the operating-model level. Instead of asking where GenAI can be applied, leaders should ask which function, process, and sub-process it can improve, and what governed workflow should support it. This approach helps organizations identify high-value opportunities across the pharmaceutical value chain while preserving the accountability, traceability, and review discipline the industry depends on.

This article explores how generative and agentic AI can support pharmaceutical operations at the operating-model level. It breaks pharmaceutical operations into industry-native functions, decomposes each function into processes and sub-processes. The focus is on helping pharmaceutical organizations identify practical AI opportunities that fit into existing systems, support governed decision-making, and keep human accountability central.

• How generative AI is transforming pharmaceutical operations
• Why pharmaceutical AI use cases must be mapped at the sub-process level
• Pharmaceuticals operating model and generative AI opportunity mapping across pharmaceutical processes
• High-value generative AI use cases in pharmaceuticals
• How agentic AI works in pharmaceutical workflows
• How to prioritize generative AI use cases in pharmaceuticals
• Governance, risk, and responsible AI in pharmaceuticals
• How ZBrain operationalizes generative AI use cases in pharmaceuticals
• Future of generative AI in pharmaceuticals

How generative AI is transforming pharmaceutical operations

Pharmaceutical teams have relied for years on analytics, rules engines, statistical models, laboratory automation, and robotic process automation to improve efficiency and consistency. These technologies remain important, but generative and agentic AI introduce a different class of capability.

Traditional automation follows predefined rules. Machine learning predicts, scores, detects, or classifies based on historical patterns. Generative AI can read, summarize, draft, compare, explain, and transform regulated content. Agentic AI can go further by coordinating a sequence of workflow steps, such as retrieving a toxicology study report, extracting relevant findings into a draft module input, flagging traceability gaps, and routing the package to a regulatory affairs lead for confirmation.

Consider batch release review. A release decision may depend on a manufacturing deviation in one system, a laboratory investigation in another, and a supplier email thread explaining a raw material delay. A rules engine can advance the case when required fields are complete, and a predictive model can score the likelihood that similar deviations previously led to rework. At that point, a generative model can turn scattered evidence into a draft deviation summary, while an agentic workflow routes unresolved evidence gaps to the quality assurance reviewer. This changes how expert time is used, with less effort spent rebuilding the record and more focused on assessing whether the evidence supports the conclusion.

In pharmaceuticals, this changes how teams handle work that is:

• Document-heavy: Batch production records, regulatory submission modules, clinical study reports, supplier quality agreements, and certificates of analysis, where extracting key evidence into a draft review packet reduces manual copying and gives reviewers a consistent starting point.
• Narrative-heavy: Adverse event case narratives, deviation investigations, medical information responses, benefit-risk assessments, and health authority response drafts, where model-generated first drafts help specialists spend more time checking causality, rationale, traceability, and wording.
• Exception-heavy: Out-of-specification results, out-of-trend signals, product complaints, change control impact questions, and supply allocation exceptions, where classifying issues with cited evidence helps teams prioritize high-risk cases sooner.
• Knowledge-heavy: Standard operating procedure interpretation, labeling precedent research, protocol eligibility questions, and chemistry, manufacturing, and controls history, where retrieval grounded in approved sources reduces ambiguity in day-to-day guidance.
• Workflow-heavy: Clinical trial startup, promotional review, regulatory variation preparation, and corrective and preventive action follow-up, where governed agents can prepare next-step tasks, identify blockers, and route work across functions so cycle time is not lost between handoffs.

The strongest pharmaceutical GenAI use cases usually do not remove the human from the process. Instead, the system prepares the case, retrieves evidence, drafts the output, flags gaps, and routes the work to the right reviewer. Before any production change, customer-facing message, submission content, or other risk-bearing action is advanced, the designated reviewer for that workflow confirms the output. This shortens review cycles without weakening regulated accountability.

Why pharmaceutical AI use cases must be mapped at the sub-process level

Pharmaceutical AI use cases become actionable only when they are tied to specific workflows, artifacts, systems, review points, and accountable owners. “AI for pharma” is too broad to be useful. So are categories such as “AI for R&D,” “AI for quality,” or “AI for regulatory.” These labels may work for strategy discussions, but they are too high-level to define data requirements, controls, approval paths, success metrics, or implementation scope.

Consider an early discovery meeting where one team wants AI to summarize disease biology, while another wants help deciding which compound analogs should advance into the next design-make-test-analyze cycle. On a portfolio slide, both may appear to be discovery AI use cases. In practice, they touch different scientific sources, lab records, assay outputs, decision points, and review paths. Treating them as a single use case blurs scope, risk, and ownership.

The work becomes executable only when it is named at the sub-process level, tied to a specific artifact, placed at a defined review point, and assigned to an accountable owner before any changes to study plans, making requests, submission inputs, or regulated decisions.

A better approach maps use cases to the pharmaceutical operating model:

• Function: The major business or control area, such as research and discovery, clinical development, pharmacovigilance, CMC, manufacturing operations, quality, regulatory affairs, or medical affairs.
• Process: The workflow within that function, such as protocol and study design, individual case safety report processing, CMC dossier management, batch disposition, deviation management, or medical information response handling.
• Sub-process: The specific activity within the workflow, such as clinical study protocol authoring, MedDRA coding and seriousness assessment, eCTD Module 3 quality dossier assembly, deviation summary drafting, or response letter preparation.
• AI-enabled opportunity: The specific way AI can support that sub-process, such as extracting findings, drafting a narrative, comparing evidence against controlled standards, classifying evidence gaps, preparing reviewer-ready summaries, or assembling a submission-ready package.

This level of detail matters because pharmaceutical workflows are tied to specific regulations, controlled documents, validated systems, scientific owners, and decision rights. A workflow for drafting a CIOMS case narrative differs from that for authoring a CMC section. A protocol amendment rationale is different from a promotional claim substantiation review. A deviation investigation summary is different from a batch release recommendation.

For example, in disease biology and target rationale review, AI can summarize selected literature and internal findings into a draft target rationale memo, which the translational science lead confirms before it informs target selection. During assay selection and qualification, potential assay methods are assessed against predefined qualification criteria, and a draft assay qualification summary is created. The bioassay development lead then confirms the selected approach before it is included in the test plan.

Mapping AI at the sub-process level moves pharmaceutical organizations from broad innovation ideas to executable workflows with clear value, data requirements, governance, and review boundaries. The operating model should not begin with a tool catalog; it should begin with how work moves from scientific rationale to regulated evidence.

Pharmaceuticals operating model and generative AI opportunity mapping across pharmaceutical processes

The following sections map generative AI opportunities across the operating model of a modern pharmaceutical organization. The model is organized into essential industry-native functions, each covering major processes, representative sub-processes, and AI-enabled opportunities.

Function 1. Discovery research, translational medicine, and preclinical development

Discovery research, translational medicine, and preclinical development cover early scientific work from disease biology and target rationale through candidate nomination, translational hypotheses, and investigational new drug-enabling nonclinical packages. These workflows depend on research data, assay outputs, electronic lab notebook records, laboratory information management systems, literature evidence, compound registries, and nonclinical study reports.

Generative AI can help teams summarize evidence, compare assay and study records, draft rationale documents, and prepare nonclinical module inputs. Agentic AI can coordinate evidence retrieval across research, lab, and regulatory systems while keeping scientific and regulatory reviewers responsible for final decisions.

The highest-value opportunities in this function are test data capture and assay result review, toxicology study report review, and IND nonclinical module inputs. These workflows combine repeated evidence reconciliation, artifact-rich lab and study records, and clear human review boundaries.

An example agentic workflow is IND nonclinical evidence assembly. The agent plans the IND nonclinical evidence checklist and retrieves toxicology reports, assay results, and study notes from approved systems. It then drafts an eCTD-aligned module input with cited gaps, routes it through the regulatory workflow, and waits for regulatory affairs lead confirmation.

Function 2. Chemistry, manufacturing, and controls (CMC)

Chemistry, manufacturing, and controls covers pharmaceutical development, drug substance and drug product control strategy, specifications, stability, analytical methods, technology transfer, and lifecycle management. CMC work is highly document and evidence-intensive because teams must reconcile development records, batch history, stability data, specifications, certificates of analysis, and regulatory commitments.

Generative AI can support CMC teams by drafting structured dossier sections, comparing specifications against evidence, summarizing stability trends, and identifying change impacts. Agentic AI can coordinate multi-step workflows across development, quality, regulatory, and publishing systems.

The highest-value GenAI opportunities in this function are CMC section authoring, eCTD Module 3 quality dossier assembly, and change control impact assessment. These workflows are artifact-rich, repetitive, and tightly connected to submission quality and lifecycle governance.

An example agentic workflow is Module 3 dossier readiness. The agent plans the required quality sections and retrieves development records, certificates of analysis, deviation and change control records, and stability reports. It then drafts placement notes and traceability gaps, routes the package through publishing, and asks the regulatory CMC reviewer to confirm submission readiness.

Function 3. Clinical development

Clinical development owns clinical strategy, protocol design, benefit-risk framing, clinical content, and study reporting from early clinical planning through registration packages. This function depends on protocols, investigator brochures, informed consent forms, clinical study reports, statistical outputs, safety data, and eCTD clinical modules.

Generative AI can help draft and compare controlled clinical content, summarize study evidence, identify protocol inconsistencies, and prepare clinical submission inputs. Agentic AI can coordinate drafting and review workflows across clinical, medical writing, safety, regulatory, and data systems.

The highest-value opportunities are clinical study protocol authoring, clinical study report authoring, and eCTD Module 2.7 clinical summary inputs. These workflows combine structured templates, repeated evidence reuse, and clear review boundaries.

An example agentic workflow is clinical study report drafting. The agent plans the CSR outline and retrieves the final protocol, amendment history, approved tables, listings, figures, safety narratives, and TMF references. It then drafts GCP-aligned CSR sections, routes unresolved claims and appendix gaps, and waits for CSR lead confirmation.

Function 4. Clinical operations

Clinical operations owns trial execution from feasibility and site activation through monitoring, enrollment, trial master file completeness, closeout, and inspection readiness. These workflows involve high volumes of site documents, activation checklists, monitoring notes, electronic case report forms, protocol deviations, and eTMF artifacts.

Generative AI can classify documents, draft site correspondence, summarize feasibility responses, prepare monitoring follow-ups, and identify missing essential documents. Agentic AI can coordinate site activation, monitoring, and TMF workflows while keeping clinical operations owners accountable.

The highest-value opportunities are essential document collection, source data verification and review, and eTMF document filing. These workflows are high-volume, repetitive, and tied to clear clinical operations review roles.

An example agentic workflow is a clinical trial site activation document follow-up. The agent plans the next activation follow-up and retrieves Form FDA 1572, ICF, investigator brochure, training, and ethics approval status. It then drafts a site-ready request with evidence links and waits for the site activation specialist’s confirmation.

Function 5. Biostatistics and clinical data management

Biostatistics and clinical data management cover statistical design, data capture, data cleaning, medical coding, database lock, analysis datasets, tables, listings, and figures. These workflows depend on protocols, case report forms, EDC systems, coding dictionaries, laboratory transfers, data review listings, and statistical analysis plans.

Generative AI can draft data review packages, prepare query text, summarize coding exceptions, compare laboratory and EDC records, and support traceable handoffs from clinical data to study reporting.

The highest-value generative AI opportunities are query generation and resolution, data review meeting package preparation, and analysis dataset specification. These sub-processes support faster data cleaning, stronger traceability, and smoother database lock readiness.

An example agentic workflow is the data review meeting package workflow. The agent retrieves open query, coding, lab reconciliation, and analysis dataset status data, drafts a prioritized issue package, routes owner queues, and records clinical data manager confirmation.

Function 6. Regulatory affairs

Regulatory affairs owns regulatory strategy, application planning, submission content coordination, eCTD publishing, labeling, health authority responses, commitments, and post-approval lifecycle management. These workflows require close coordination across clinical, quality, CMC, safety, labeling, and publishing teams.

Generative AI can support dossier planning, submission readiness checks, response drafting, labeling comparison, and regulatory commitment tracking. Agentic AI can coordinate evidence retrieval and review routing across regulatory information management, document management, quality, and publishing systems.

The highest-value GenAI opportunities are eCTD publishing and submission readiness, health authority question management, and CMC change filing assessment. These workflows are deadline-driven, evidence-heavy, and well-suited to AI-assisted comparison and response drafting.

An example agentic workflow is the health authority response workflow. The agent plans the response package and retrieves the question letter, clinical study report, stability report, change control record, and prior commitments. It then drafts response outlines with evidence links, routes unresolved issues, and records regulatory strategy lead confirmation.

Function 7. Pharmacovigilance and drug safety

Pharmacovigilance and drug safety cover adverse event intake, individual case safety report processing, duplicate detection, medical review, expedited reporting, signal management, aggregate safety reporting, and safety compliance. These workflows are high-volume, time-sensitive, and governed by strict reporting expectations.

Generative AI can extract case details, draft narratives, summarize causality and expectedness evidence, support duplicate review, and prepare aggregate safety content. Agentic AI can coordinate intake, follow-up, narrative drafting, and medical review while keeping safety decisions with qualified reviewers.

The highest-value generative AI opportunities are duplicate case detection, CIOMS narrative preparation, and medical review and safety signal management. These workflows are high-volume or high-consequence and require strong human medical review.

An example agentic workflow is the expedited safety case narrative workflow. The agent plans the case completion checklist, retrieves source correspondence, ICSR data, and label context. It then drafts the CIOMS narrative and CIOMS I form, routes ambiguous issues of seriousness, causality, expectedness, and deadlines to the medical safety physician, and records confirmation.

Function 8. Manufacturing operations

Manufacturing operations cover shop-floor execution for drug substance, drug product, packaging, batch documentation, in-process controls, serialization, and release-ready production records. These workflows depend on master production records, electronic batch records, production orders, equipment data, certificates of analysis, deviations, and quality release queues.

Generative AI can summarize batch record anomalies, draft shift handover notes, compare records against procedures, and prepare release-readiness summaries. Agentic AI can coordinate evidence across manufacturing, quality control, quality assurance, and supply chain systems.

The highest-value GenAI opportunities are electronic batch record review, batch production record exception review, and continued process verification trending. These workflows reduce manual record review, shorten release cycle time, and strengthen evidence quality for batch disposition.

An example agentic workflow is a batch release readiness review. The agent retrieves the production order, electronic batch record, certificate of analysis, deviation records, and open quality issues. It then drafts exception summaries and reconciliation questions, routes the package to the QA batch release queue, and records QA confirmation.

Function 9. Quality assurance and quality control

Quality assurance and quality control own the pharmaceutical quality system, batch disposition, deviation management, CAPA governance, OOS and OOT investigations, QC testing, stability, validation oversight, data integrity, and inspection readiness. These workflows are evidence-heavy and often require manual assembly across batch records, lab systems, audit trails, SOPs, and quality events.

Generative AI can draft investigation summaries, compare quality records against standards, summarize CAPA evidence, identify data integrity exceptions, and assemble inspection-ready evidence packs.

The highest-value GenAI opportunities are deviation investigation support, OOS investigation support, CAPA effectiveness checks, and ALCOA+ data integrity review. These workflows reduce manual evidence assembly and strengthen compliance traceability while keeping final judgment with QA, QC, and data integrity owners.

An example agentic workflow is a deviation investigation and evidence assembly. The agent retrieves the deviation report, batch record exceptions, LIMS results, SOPs, CAPA history, and validation references. It then drafts a risk-aligned investigation summary with evidence gaps, routes the package through the quality system, and asks the QA manager to confirm disposition.

Function 10. Supply chain and external manufacturing

Supply chain and external manufacturing cover demand planning, supply planning, materials availability, external manufacturing coordination, batch release dependencies, distribution, cold chain, serialization, and supply continuity. These workflows are complex because planning decisions depend on quality events, batch status, supplier notifications, market demand, logistics records, and regulatory constraints.

Generative AI can summarize constrained-supply scenarios, supplier change impacts, batch release dependencies, and temperature excursion evidence. Agentic AI can coordinate planning, external manufacturing, quality, and logistics workflows while preserving final decision rights.

The highest-value GenAI opportunities are supply plan and allocation review, batch record transfer and review, and temperature excursion documentation. These workflows connect planning, quality, and release decisions while preserving accountable review.

An example agentic workflow is external batch release and allocation triage. The agent retrieves production schedules, allocation constraints, batch records, deviations, CAPA records, and certificates of analysis. It then drafts a release-risk and allocation impact summary, routes the package to external manufacturing operations, and records confirmation before the next planning action.

Function 11. Medical affairs

Medical affairs owns medical strategy, scientific communication, medical information, field medical engagement, publication planning, congress support, investigator-sponsored research review, and medical input to content governance. These workflows require alignment with approved labels, prescribing information, clinical evidence, safety context, and medical review standards.

Generative AI can support literature synthesis, scientific response drafting, field insight summarization, medical review preparation, and evidence consistency checks. Agentic AI can route safety, off-label, or compliance-sensitive items to the right owners.

The strongest GenAI opportunities are scientific response letter development, literature evidence summaries, insight tagging and triage, and claim substantiation review. These workflows reduce manual evidence handling while preserving medical judgment.

An example agentic workflow is the scientific response letter workflow. The agent retrieves inquiry details, approved label, prescribing information, clinical study reports, and relevant references. It then drafts a citation-linked response, routes adverse event exceptions to safety, flags off-label issues, and waits for medical information specialist confirmation.

Function 12. Market access, pricing, and HEOR

Market access, pricing, and health economics and outcomes research cover access strategy, pricing, reimbursement, payer evidence, health technology assessment dossiers, real-world evidence, and post-launch evidence generation. These workflows require consistent reuse of clinical, economic, humanistic, and real-world evidence across markets and payer contexts.

Generative AI can maintain evidence dossiers, draft payer objection responses, summarize real-world evidence updates, and compare dossier content against local requirements. Agentic AI can coordinate evidence refreshes across regulatory, medical, market access, and MLR workflows.

The strongest generative AI opportunities are value dossier maintenance, payer objection response preparation, real-world evidence update summaries, and HTA dossier development. These use cases reduce manual refresh effort and improve evidence consistency across markets.

An example agentic workflow is value dossier evidence refresh. The agent retrieves approved label changes, CSR excerpts, value dossier sections, RWE tables, and payer objections, drafts updated evidence tables and response language, routes the package through review, and waits for value dossier owner confirmation.

Function 13. Commercial strategy, brand, and omnichannel engagement

Commercial strategy, brand, and omnichannel engagement cover brand planning, launch readiness, promotional content operations, customer engagement, field enablement, campaign analytics, and content reuse across channels. These workflows involve high volumes of claims, references, content modules, review annotations, channel rules, and customer engagement records.

Generative AI can support promotional packet preparation, claim library maintenance, content tagging, compliant message reuse, field call planning, and campaign performance reporting. Agentic AI can coordinate promotional review workflows while keeping medical, legal, and regulatory approval intact.

The highest-value GenAI opportunities are promotional review annotation packet preparation, claim library maintenance, content modularization and tagging, and MLR workflow support. These workflows reduce review rework, improve claim traceability, and speed compliant content operations.

An example agentic workflow is promotional review packet preparation. The agent retrieves approved label language, prescribing information, and clinical study references. It then drafts content, prepares the annotation packet, flags missing support, routes the package through the promotional review system, and records MLR coordinator confirmation.

Function 14. Technology, data, and governance

Technology, data, and governance provide the foundation for scaling AI safely across pharmaceutical operations. This function owns enterprise systems, data architecture, integrations, analytics, cybersecurity, validation, model lifecycle controls, AI governance, and regulated workflow enablement.

Generative and agentic AI can support data lineage documentation, validation planning, AI use case intake, model monitoring, access control review, prompt logging, and human approval workflow management. This function is essential because AI cannot scale in pharma without validated systems, controlled data access, audit trails, and governance.

The highest-value generative AI opportunities are data lineage and provenance capture, computer system validation planning, AI use case risk assessment, and model monitoring with human approval workflows. These capabilities create the governance foundation needed to deploy AI safely across pharmaceutical functions.

An example agentic workflow is the GxP validation impact workflow. The agent retrieves the change control record, validation master plan, executed test evidence, and data lineage records, drafts a CSV impact summary with data integrity gaps, routes the package to the validation manager, and waits for final disposition confirmation.

High-value generative AI use cases in pharmaceuticals

In pharmaceuticals, high-value generative AI use cases start at operational choke points where large volumes of regulated text or structured records must be reviewed before work can move forward. These use cases run over existing artifacts, such as protocols, batch records, safety case forms, submission modules, or review packets, and end with confirmation by a defined reviewer. This pattern reduces manual effort and cycle time without bypassing accountability.

A pharmaceutical use case earns high-value status when its business value is easy to trace through less rework, shorter review queues, clearer compliance evidence, or lower cost in a named workflow. It also needs a clean review boundary, where the medical reviewer, quality unit, regulatory lead, or safety physician can approve the output before it affects a patient, a batch, a filing, or an external response.

How agentic AI works in pharmaceutical workflows

Generative AI can draft, summarize, extract, classify, and retrieve information. Agentic AI coordinates workflows around those capabilities. In pharmaceuticals, this distinction matters because high-value work rarely sits in one document or one system. A dossier gap, batch release question, adverse event follow-up, or clinical study report section often depends on evidence spread across study reports, lab records, quality systems, regulatory repositories, safety databases, and review notes.

An agentic workflow in pharmaceuticals follows a governed sequence. The system plans the work, retrieves approved source material, prepares a draft or evidence pack, checks for gaps, routes the output for review, and waits for human confirmation before any risk-bearing action is taken. Tool access remains limited to approved clinical, regulatory, quality, manufacturing, safety, or lab systems, reducing manual effort while keeping review accountability clear.

Examples of agentic AI workflows in pharmaceuticals include:

Investigational new drug nonclinical evidence assembly

An IND nonclinical evidence agent retrieves toxicology study reports, assay results, and study notes from approved source systems. It drafts eCTD-aligned module inputs, flags traceability gaps, and routes the package to the regulatory affairs lead for readiness confirmation.

Module 3 dossier readiness workflow

A Module 3 readiness agent retrieves development records, analytical method documents, certificates of analysis, stability data, deviation records, and manufacturing process descriptions from approved systems. It identifies missing evidence, drafts placement notes, summarizes traceability gaps, and routes the package to the regulatory CMC reviewer before submission content is finalized.

Clinical study report drafting workflow

A CSR drafting agent retrieves the final protocol, amendment history, statistical outputs, tables, listings, figures, safety narratives, and prior approved language. It drafts GCP-aligned report sections, flags unresolved claims or appendix gaps, and routes the draft to the CSR lead for publishing readiness confirmation.

Clinical trial site activation document follow-up

A site activation agent retrieves Form FDA 1572 status, informed consent form status, investigator brochure status, site contract status, ethics approval records, and required training evidence from approved trial systems. It drafts site-ready follow-up requests with evidence links and routes the packet to the site activation specialist before activation-ready status is confirmed.

Deviation investigation support

A deviation investigation agent retrieves the deviation record, batch record entries, environmental monitoring results, equipment logs, SOP requirements, prior related deviations, and CAPA history. It prepares an investigation summary, identifies likely evidence gaps, drafts initial CAPA language, and routes the case to the quality assurance reviewer before any investigation conclusion or production decision is advanced.

Adverse event follow-up workflow

A safety case agent extracts information from intake forms, emails, call notes, lab attachments, and follow-up correspondence. It identifies missing seriousness, causality, concomitant medication, or outcome details, drafts follow-up questions, and routes the case to the safety case processor or pharmacovigilance physician before submission or escalation.

In regulated pharmaceutical workflows, the control point must remain human. The agent prepares evidence, drafts content, identifies gaps, and routes work, but the accountable owner confirms the output before it affects a regulatory filing, batch disposition, site activation status, safety submission, customer-facing response, or production change.

How to prioritize generative AI use cases in pharmaceuticals

Pharmaceutical organizations should not select generative AI use cases only because they sound innovative. The strongest use cases combine business value, workflow fit, data readiness, control readiness, and scalability. This discipline matters because many agentic AI projects fail when costs rise, business value is unclear, or risk controls are inadequate.

Each use case should be scored against clear prioritization criteria, then sequenced based on where GenAI can prepare a reviewer-ready draft, evidence pack, exception summary, or governed workflow for an accountable process owner to confirm.

Pharmaceutical AI portfolios often stall for predictable reasons. Some pilots start at the wrong altitude, with use cases defined too broadly to test workflow fit. Others stall because the required source data, metadata, or system access is not ready. Later-stage pilots can lose momentum when governance is added too late, reviewer accountability is unclear, or the value case cannot be traced to a named workflow.

A practical first wave should focus on high-volume, artifact-rich, cleanly reviewed sub-processes already flagged in the operating model, such as CSR authoring, deviation and CAPA drafting, ICSR processing, eCTD publishing readiness, and promotional MLR support. More sensitive uses, such as workflows that influence batch disposition, submission commitments, causality determinations, or label content, require stronger validation evidence and must keep final accountability with designated personnel.

Governance, risk, and responsible AI in pharmaceuticals

Generative AI in pharmaceuticals must operate within the organization’s existing governance, quality, regulatory, and control environment. Governance starts at the review point, and the most important principle is clear accountability: AI can assist with evidence retrieval, drafting, summarization, classification, and workflow coordination, but the responsible human owner remains accountable for consequential decisions and regulated outputs.

• Human-in-the-loop oversight: In pharmaceuticals, the highest-risk AI-enabled decision points often sit inside familiar handoffs, such as toxicology study report review, IND nonclinical module inputs, deviation investigation support, batch record review, or safety case processing. AI may draft a summary, compare evidence, or classify gaps, but the study director, regulatory affairs reviewer, quality assurance reviewer, clinical scientist, safety physician, or quality unit confirms the output before any production change, customer-facing message, submission content, batch disposition, or other risk-bearing action moves forward.
• Regulatory and standards alignment: Governance should connect AI behavior to controlled pharmaceutical workflows rather than treating AI as a separate technology lane. Frameworks such as the NIST AI Risk Management Framework and the NIST Generative AI Profile can help teams manage risks related to hallucination, provenance, misuse, data leakage, and unsupported outputs. In regulated pharmaceutical settings, this AI governance layer should align with applicable FDA expectations for electronic records, GLP, cGMP, IND and NDA submissions, biologics requirements, and AI-supported regulatory decision-making. It should also reflect established validation, quality risk management, cybersecurity, documentation, and human oversight principles used across global pharmaceutical programs.
• Bias mitigation and evidence retention: Bias can enter early in the workflow, especially when target rationale review overweights familiar pathways, patient stratification relies on narrow datasets, or medical and safety summaries rely on incomplete source material. Reviewers should retain the source artifacts that shaped each output, such as literature search records, assay qualification reports, clinical study reports, safety narratives, or quality records. This allows accountable reviewers to challenge the basis for an AI-generated conclusion instead of reviewing only a polished summary.
• Use-case inventory and risk tiering: Pharmaceutical organizations should maintain a use-case inventory that distinguishes low-risk drafting and summarization from higher-risk sub-processes such as critical quality attribute identification, protocol and study design, safety pharmacology package preparation, causality assessment, batch disposition support, or submission commitment tracking. Risk tiering should determine approval gates, validation expectations, monitoring requirements, and escalation paths for low-confidence, conflicting, or incomplete outputs.
• Grounding, access, and workflow controls: Outputs should be based on approved pharmaceutical sources, such as controlled procedures, validated study documents, quality records, current regulatory guidance, approved labeling, and authorized repositories. Least-privilege and role-based access controls should limit what the model can retrieve, while scoped tool access should define what an agent can and cannot do. For example, an agent may prepare a draft change rationale or summarize a lifecycle management record, but it should not update the record until the change control owner confirms the action.
• Traceability, monitoring, and data security: Each governed workflow needs an audit trail that captures prompts, approved sources, model version, reviewer disposition, approvals, and any downstream system action. These records should support review under requirements and frameworks such as 21 CFR Part 11, the NIST Cybersecurity Framework 2.0, ISO/IEC 27001:2022, and the AICPA Trust Services Criteria. Monitoring should track accuracy, completeness, unsupported claims, missing citations, model drift, access exceptions, reviewer overrides, and exception rates. Data protection must also cover study data, formulation knowledge, nonclinical reports, safety records, quality documentation, and regulatory correspondence.

Governance is not a blocker to pharmaceutical AI adoption. When designed well, governed AI workflows can create more transparency, stronger documentation, better traceability, and clearer accountability than unmanaged manual work.

How ZBrain operationalizes generative AI use cases in pharmaceuticals

Identifying generative AI use cases is only the first step. Pharmaceutical organizations also need a structured way to design, validate, deploy, govern, and scale AI workflows across regulated functions such as clinical development, regulatory affairs, pharmacovigilance, quality, manufacturing, medical affairs, and commercial operations.

This is where ZBrain can help. ZBrain is an end-to-end AI enablement platform that supports the full lifecycle of enterprise AI adoption, from identifying high-value opportunities to designing, building, validating, and scaling governed AI workflows. For pharmaceutical organizations, this means AI initiatives can be tied to specific processes, source systems, review points, KPIs, and accountable owners rather than remaining isolated pilots.

ZBrain supports this lifecycle through six connected stages:

Preparation (foundation)

Establishes a comprehensive understanding of the organization’s current enterprise environment, including processes, technology systems, workforce metrics, and KPIs, providing the insight needed to identify where AI can deliver meaningful value.

Ideation & prioritization (discovery)

Leverages enterprise data to identify AI opportunities and then prioritizes them based on feasibility, cost, benefits, and potential ROI, with priority given to those that can be embedded within existing processes.

Solution design (validation)

Translates prioritized opportunities into ROI-validated and KPI-mapped solution design blueprints, defining where AI can assist, augment, or act autonomously within workflows.

Technical design (Build-ready)

Transforms solution requirements into structured, build-ready technical design artifacts, including architecture diagrams, schemas, agentic workflows, user stories, epics, and business requirement documents. This provides the build team with a complete technical design to serve as a foundation for development.

Proof of concept / PoC (validation)

Tests selected AI solutions in controlled environments to validate feasibility, business value, and implementation readiness before scaling.

Scaled product

Scale validated proof-of-concept, supported by performance metrics and observability data, are deployed as governed, production-grade AI solutions across enterprise environments, with continuous improvement loops to sustain impact.

Future of generative AI in pharmaceuticals

The next phase of generative AI in pharmaceuticals will be defined less by standalone copilots and more by governed, cross-functional workflows that connect evidence, systems, reviewers, and decisions.

From isolated copilots to governed enterprise workflows

In the next few years, generative AI in pharmaceuticals will move beyond isolated copilots and become part of governed enterprise workflows. This shift is necessary because pharmaceutical work rarely sits within a single function or system. A regulatory question may depend on submission history, while the supporting evidence may sit across clinical, safety, quality, manufacturing, and regulatory systems. The practical need, therefore, is a shared foundation that can coordinate access, apply governance, capture observability, and connect AI outputs to approved workflows.

This direction reflects a broader enterprise shift toward agent-enabled applications. Gartner [3] projects that 40 percent of enterprise applications will include task-specific AI agents by the end of 2026, up from less than 5 percent in 2025. It also projects that 33 percent [4] of enterprise software applications will include agentic AI by 2028, up from less than 1 percent in 2024. For pharmaceutical organizations, the implication is not simply more automation. It is the need to make AI workflows governable, traceable, and reviewable before they affect regulated processes.

Federated platforms for cross-functional adoption

Federated platforms will become increasingly important as pharmaceutical organizations scale AI across research, regulatory affairs, pharmacovigilance, medical affairs, manufacturing, quality, and commercial operations. These platforms can provide common orchestration, access control, monitoring, and governance patterns without forcing every function into the same workflow design.

This matters because each pharmaceutical function has its own source systems, artifacts, review roles, and risk boundaries. A pharmacovigilance workflow may need safety databases and case narratives, while a quality workflow may need batch records, SOPs, deviations, CAPA history, and environmental monitoring records. A federated approach helps reduce duplicated setup, gives compliance teams clearer review trails, and allows accountable reviewers to confirm AI-supported outputs before they affect submissions, safety actions, quality records, or external communications.

Longer-horizon agentic workflow support

Once the shared foundation is in place, the next shift will be longer-horizon agentic workflow support. Instead of stopping after a single summary, draft, or classification task, agentic workflows can sustain progress across multi-step pharmaceutical goals.

In pharmacovigilance, an agentic workflow could assemble source narratives, compare them with approved case-handling guidance, identify missing follow-up details, and prepare a draft case assessment for safety physician review before reporting action is taken. In quality, the same pattern could help structure a deviation investigation by retrieving procedure language, batch context, prior deviations, and CAPA history while a quality assurance reviewer confirms conclusions before any controlled record is updated.

The value is not autonomy for its own sake. It is shorter cycle time, stronger evidence traceability, better reviewer focus, and clearer accountability at the exact points where pharmaceutical decisions carry patient, regulatory, or product-quality risk.

Workflow design as the differentiator

As governed AI workflows mature, model selection will become less important than workflow design. Frontier models will continue improving in their ability to summarize, classify, retrieve, reason over, and draft pharmaceutical content. The stronger differentiator will be whether organizations have defined the handoffs, source systems, review roles, escalation rules, validation expectations, and evidence capture needed for reliable use in controlled environments.

A medical affairs team, for example, may gain more from a well-designed review path for scientific response drafting than from switching between similar frontier models without changing the approval process around the output. A regulatory team may see more impact from structured evidence retrieval and response routing than from a standalone drafting assistant. A quality team may gain more from traceable investigation support than from generic summarization.

The future of generative AI in pharmaceuticals will therefore be shaped by process architecture. Models will provide the language, reasoning, and retrieval layer, but workflow design will determine whether AI reduces manual effort, improves decision quality, strengthens compliance evidence, and gives each reviewer a clear point of control.

Endnote

Generative AI has the potential to reshape pharmaceutical work, but only when it is applied at the right level of detail. High-level generative AI opportunities can set direction, but execution requires defined workflows, source data, outputs, control points, and accountable owners. Real value comes from mapping AI to specific workflows such as toxicology study report review, CMC section authoring, clinical study report drafting, eCTD publishing readiness, ICSR narrative preparation, deviation and CAPA management, promotional MLR review, and HTA dossier maintenance.

The pharmaceutical operating model is complex, spanning discovery, CMC, clinical development, clinical operations, biostatistics and data management, regulatory affairs, pharmacovigilance, manufacturing, quality, supply chain, medical affairs, market access, commercial engagement, and the underlying technology and governance layer. Across these functions, generative AI can extract evidence, summarize regulated records, draft narratives, classify exceptions, retrieve approved guidance, and prepare reviewer-ready outputs. Agentic AI extends this value by coordinating multi-step workflows across research, clinical, regulatory, safety, quality, manufacturing, and enterprise systems while keeping human review in place.

For pharmaceutical organizations, the path forward is to build a sub-process-level opportunity map, prioritize workflows with strong value, available source artifacts, and clear review ownership, and connect AI to approved data and validated systems. From there, pharmaceutical organizations can run controlled pilots, deploy with governance, auditability, and role-based access, and scale through reusable agents, components, and orchestration patterns. Generic chatbots will not define the future of pharmaceutical AI. It will be defined by governed, workflow-specific agents that help organizations reduce manual effort, strengthen controls, improve decision quality, and give experts more time to apply judgment where patient, regulatory, and product-quality risk is highest.

Operationalize GenAI across pharma workflows with ZBrain. ZBrain helps pharmaceutical enterprises build governed AI workflows across key functions, reducing manual effort while strengthening traceability and review efficiency. Connect with the ZBrain team today!